𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients

✍ Scribed by R. Jardi; F. Rodriguez-Frias; M. Schaper; G. Ruiz; I. Elefsiniotis; R. Esteban; M. Buti


Book ID
108886032
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
54 KB
Volume
0
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Entecavir resistance is rare in nucleosi
✍ Richard J. Colonno; Ronald Rose; Carl J. Baldick; Steven Levine; Kevin Pokornows πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 378 KB

a HBV DNA Ο½7 Ο« 10 5 copies/mL by bDNA assay Ο© loss of HBeAg (Study AI463022) or normalization of ALT (Study AI463027). b HBV DNA Ο½7 Ο« 10 5 copies/mL by bDNA assay. c HBV DNA Υ†7 Ο« 10 5 copies/mL by bDNA assay.

In vitro evaluation of hepatitis B virus
✍ Xiaofeng Xiong; Huiling Yang; Christopher E. Westland; Ruiming Zou; Craig S. Gib πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 134 KB πŸ‘ 1 views

Several mutations (V521L, P525L, L528M, T532S, and V555I) in the gene for hepatitis B virus (HBV) polymerase have been identified in HBV isolated from patients that displayed break-through viremia during famciclovir treatment. To determine whether these mutations cause phenotypic resistance to famci

Naturally occurring dominant resistance
✍ Thomas Kuntzen; Joerg Timm; Andrew Berical; Niall Lennon; Aaron M. Berlin; Sarah πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 263 KB

Resistance mutations to hepatitis C virus (HCV) nonstructural protein 3 (NS3) protease inhibitors in <1% of the viral quasispecies may still allow >1000-fold viral load reductions upon treatment, consistent with their reported reduced replicative fitness in vitro. Recently, however, an R155K proteas